Himalaya Therapeutics develops combination cancer therapies using its proprietary Conditionally Active Biologics (CAB) platform, which creates antibodies that bind reversibly only to tumor‑cell targets, enhancing safety and potency. By focusing on differentiated, high‑window therapeutics, the company aims to deliver more effective treatments with reduced side effects. Their pipeline includes CAB‑based candidates that have shown promising safety and efficacy in non‑human primate and early patient studies.
Funding
Funding not disclosed
Founders
Product
Problem
Current antibody cancer therapies often have limited therapeutic windows, leading to off‑target toxicity and restricting the doses that can be administered, which reduces efficacy for patients with solid tumors.
Solution
Himalaya Therapeutics leverages its proprietary Conditionally Active Biologics (CAB) platform to create antibodies that bind reversibly only within the acidic tumor microenvironment. By remaining inactive in normal tissues and activating selectively at tumor sites, CAB antibodies achieve higher on‑target potency while minimizing off‑target effects, thereby widening the therapeutic window. The platform supports multiple formats, including antibody‑drug conjugates (ADCs) and bispecifics, enabling the development of combination regimens. Lead candidates targeting AXL and ROR2 have demonstrated safety and potency in non‑human primates and early‑phase clinical trials across sarcoma, NSCLC, and melanoma. Himalaya advances these candidates through independent development and strategic partnerships to bring safer, more effective oncology treatments to market.
Target Audience
Primary customers are oncology pharmaceutical companies and clinical investigators seeking to develop or co‑develop high‑potency, low‑toxicity antibody therapeutics for solid tumors, particularly in the Greater China market.
Features
- pH‑responsive antibody design that activates binding in the acidic tumor microenvironment and deactivates in normal tissue
- Reversible activation allows repeated tumor entry without cumulative off‑target exposure
- Platform compatibility with ADCs, bispecific antibodies, and other biologic formats for combination therapy development
- Lead clinical candidates (CAB‑AXL‑ADC and CAB‑ROR2‑ADC) with Phase 1/2 data showing high safety and efficacy signals in sarcoma, NSCLC, and melanoma
- Extensive patent portfolio covering over 500 granted and pending inventions related to the CAB technology
- Integrated development capability from discovery through commercialization, supported by collaborations with BioAtla and regional CRO networks